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1. Introduction  
Protein toxins are prominent virulence factors in many pathogenic bacteria. While toxins of 
Gram-positive bacteria do not generally require activation, many toxins of the Gram-
negatives are translated into an inactive form and require a processing step. 
The most common such step involves a proteolytic cleavage to generate the active form, 
especially in those toxins with enzymatic activity. Toxins are activated by proteolysis in a 
variety of ways: As examples, the anthrax toxin is proteolyzed after its interaction with 
the receptor on the target cell to promote the formation of a prepore (van der Goot & 
Young, 2009); the toxic subunit of the Vibrio cholerae toxin (CT) is posttranslationally 
modified through the action of a V. cholerae protease that generates two fragments, one 
containing the toxic activity and the other serving to interact with the binding domain 
(Sanchez & Holmgren, 2011); finally, the toxins that are synthesized as a single 
polypeptides must be separated by proteolytic cleavage to generate a catalytic, a 
transmembrane, and a receptor-binding domain—a salient example here being the 
diphtheria toxin (Murphy, 1996). 
Another processing step involves the acylation of proteins, which substitution is achieved 
by various mechanisms that differ according to the particular fatty acid transferred, the 
modified amino acid, and the fatty-acyl donor. Myristate and palmitate are the most 
common fatty acids cross-linked to proteins. Proteins sorted to the bacterial outer membrane 
or to the eukaryotic plasma membrane undergo processing in which an acyl group is 
attached to the N-terminal amino acid. In prokaryotes, acyltransferase, lipases, or esterases 
use catalytic mechanisms involving ester-linked acyl groups attached to serine and cysteine 
residues; while eukaryotic proteins utilize ester-linked palmitoylation and ether-linked 
prenylation of cysteine residues for membrane sorting and protein-protein interaction 
(Stanley et al., 1998). 
The pore-forming α-hemolysin (HlyA) of Escherichia coli, a member of the RTX toxins, 
represents a unique class of bacterial toxins that require for activation a posttranslational 
modification involving a covalent amide linkage of fatty acids to two internal lysine 
residues (Stanley et al., 1998). In general, protein acylation is divided into labile 
modifications of internal regions and stable modifications at the N and C termini. By 
contrast, the mechanism of stable internal acylation of HlyA represents a unique example 






introducing HlyA, its synthesis, posttranslational modification, secretion, and activity; this 
chapter will focus on the role that covalently bound fatty acids play in the toxin's 
mechanism of action. 
In recent decades, scientific advances have permitted the manipulation of toxins by using 
different strategies for directing toxic moieties to diseased cells and tissues. The end of the 
chapter will involve a discussion of this so-called toxin-based therapy and the potential use of 
HlyA in that modality. 
2. The alpha-hemolysin (HlyA) of E. coli 
Extraintestinal pathogenic Escherichia coli (ExPEC) is the causative agent of at least 80% of 
all uncomplicated urinary-tract infections (UTIs), which pathologies currently rank 
among the most common of infectious diseases worldwide (Marrs et al. 2005), (Foxman & 
Brown, 2003). ExPEC strains that cause a UTI are called uropathogenic E. coli (UPEC). This 
unique group of E. coli strains can reside in the lower gastrointestinal tract of healthy 
adults (Foxman et al., 2002), (Yamamoto et al., 1997), but upon entry into the urinary tract 
can ascend to and colonize the bladder, causing cystitis. The infection may be confined to 
the bladder, or bacteria may ascend into the ureters to infect the kidneys and cause 
pyelonephritis. In severe cases, bacteria can further disseminate across the proximal-
tubular and capillary endothelia to the bloodstream, causing bacteremia (Mobley et al., 
2009.). A significant proportion of UTIs occur in patients with no known abnormalities of 
the urinary tract—the so-called uncomplicated UTIs. Certain host characteristics, however, 
such as a congenital defect in urinary-tract anatomy, are considered complicating factors 
for UTI and accordingly increase susceptibility to this infection as well as affect its 
diagnosis and management (Foxman, 2002.). Finally, colonization of the bladder in high 
numbers may occur without eliciting symptoms in the host, a condition known as 
asymptomatic bacteriuria (Hooton et al., 2000.). In recent years, an enormous amount of 
information has accrued through sequencing the genomes of several ExPEC patients. 
These data, together with epidemiological analyses, have confirmed that different ExPEC 
pathotypes share many known as well as putative virulence factors. These latter include a 
number of secreted toxins, iron-acquisition systems, adhesins, and capsular antigens 
(Wiles et al., 2008). Secreted toxins—which proteins include HlyA, the cytotoxic 
necrotizing factor-1 (CNF-1), and the secreted autotransporter—can alter host signaling 
cascades, disrupt inflammatory responses, and induce host-cell death; whereas bacterial 
siderophores like aerobactin, bacteriocin, and enterobactin allow the ExPEC to sequester 
iron away from the host (Guyer et al., 2002), (Wiles et al., 2008). Adhesive organelles can 
mediate ExPEC interaction with, and entry into, host cells and tissues; while the 
expression of encapsulation may enable ExPEC to more effectively avoid professional 
phagocytes (Wiles et al., 2008), (Dhakal et al. 2008). 
Experiments in murine and cell-culture model systems have demonstrated that high levels 
of HlyA can cause the osmotic lysis of host cells, while sublytic concentrations of this pore-
forming toxin can modulate host-survival pathways by interfering with phagocyte 
chemotaxis (Wiles et al, 2008),(Jonas et al., 1993), (Cavalieri & Snyder, 1982), (Chen et al., 
2006). Both HlyA and CNF-1 may in addition stimulate the breakdown of tissue barriers and 
the release of nutrients (Smith et al. 2008), (Bauer & Welch, 1996), but through the use of the 
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zebrafish infection model phagocytes were found that appeared to be the primary targets of 
these toxins (Wiles et al.,2009). 
HlyA represents the prototype of the first RTX family of proteins characterized by Rodney 
Welch (Welch 1991). Produced by a variety of Gram-negative bacteria, these proteins exhibit 
two common features: The first is the presence of arrays of glycine- and aspartate-rich 
nonapeptide repeats, which sequences are located at the C-terminal portion. The second is 
the unique mode of secretion via the type-I system (an ABC-binding–cassette transporter). 
This first group of RTX toxins consists of toxins—mostly exhibiting cytotoxic pore-forming 
activity—that often are first detected as a hemolytic halo surrounding bacterial colonies 
grown on blood-agar plates (Muller et al., 1983), (Welch, 1991), (Felmlee et al., 1985). Recently, 
a subgroup of very large RTX toxins (>3200 residues) were discovered with multiple 
activities, such as protease and lipase. These pathogens were named the multifunctional 
autoprocessing RTX toxins, with the Vibrio cholerae toxin being the prototype of this group. 
In summary, the RTX proteins form a large and diverse family with a broad spectrum of 
biological and biochemical activities (Linhartova, et al., 2010). 
2.1 Synthesis and structure of HlyA  
The synthesis, maturation, and secretion of E. coli HlyA are determined by the hlyCABD 
operon ((Felmlee et al, 1985), (Issartel et al., 1991), (Koronakis et al., 1997), (Nieto et al. ,1996)). 
The membrane-associated export proteins are synthesized at a lower level than the cytosolic 
HlyC and pro-HlyA, in part because of transcription termination within the hlyCABD 
operon (Felmlee et al, 1985). This termination is suppressed by the elongation protein RfaH 
and a short 59-bp, ops (operon polarity suppressor) (Bailey et al., 1992, 1996), (Cross et al., 
1990), (Nieto et al., 1996) that act in concert to allow the transcription of long operons such as 
hly, rfa, and tra encoding the synthesis and export of extracellular components key in the 
virulence and fertility of Gram-negative bacteria (Bailey et al., 1992, 1997). 
The structural gene hlyA produces a single 110-kDa polypeptide. The estimated pI of the 
toxin is 4.5, with this characteristic being common among the RTX toxins. The N-terminal 
hydrophobic domain is predicted to contain nine amphipathic ǂ-helices (Soloaga et al., 
1999). Using photoactivable liposomes, Hyland et al (2001) demonstrated that the region 
comprised between residues 177-411 is the one that becomes inserted into membranes. The 
C-terminal calcium-binding domain contains 11-17 of the glycine- and aspartate-rich 
nonapeptide ǃ-strand repeats. Although the membrane interaction of HlyA is assumed to 
occur mainly through the amphipathic ǂ-helical domain, that both major domains of HlyA 
are directly involved in the membrane interaction of HlyA has recently been proposed, with 
the calcium-binding domain in particular being responsible for the early stages of the 
HlyA's docking to the target membrane (Sanchez-Magraner et al., 2007). 
The topic of the existence of a receptor for the toxin in erythrocytes remains quite 
controversial.  Nevertheless, Cortajarena et al (2003) observed that a short sequence from the 
C-terminal domain (between residues 914–936) was the main HlyA segment that bound to 
the glycophorin A on erythrocytes. 
The last 60 C-terminal amino acids consist of 2 ǂ-helices separated by 8-10 charged residues. 
This domain is implicated in the transport of the toxin to the extracellular medium (Hui et 







Fig. 1. A scheme of the HlyA structure. 
The more relevant domains of HlyA are indicated. 
2.2 The posttranslational activation of HlyA 
The proHlyA protoxin is matured in the cytosol to the active form by HlyC-directed fatty 
acylation before export from the toxin-producing bacteria. This process consists in a 
posttranslational modification of the ε-amino groups of internal lysine residues by 
covalent attachment of amide-linked fatty-acyl residues. This reaction is catalyzed by the 
HlyC acyltransferases expressed together with the protoxins (Goebel & Hedgpeth, 1982). 
The mechanism of this novel type of protein acylation was extensively analyzed for HlyA 
(Issartel et al., 1991), (Stanley et al., 1994). HlyC uses the fatty-acyl residues carried by acyl-
carrier protein (ACP) to form a covalent acyl-HlyC intermediate, which species then 
transfers the fatty-acyl residues to the ε-amino groups of the Lys 564 and Lys 690 residues 
of proHlyA (Worsham et al., 2001, 2005). ACPs carrying various fatty-acyl residues—
including palmitate (16:0) and palmitoleate (16:1), the most common in E. coli—could be 
efficiently used in vitro as acyl donors for the modification of HlyA ((Issartel et al., 1991), 
(Trent et al., 1998)). In vivo, however, HlyC exhibits a high selectivity for myristic acid 
(14:0), which species was found to constitute about 68% of the acyl chains covalently 
linked to Lys 564 and Lys 690 of the native HlyA (Lim et al., 2000). Contrary to 
expectations, the extremely rare odd-carbon saturated fatty-acyl residues 15:0 and 17:0 
were found to constitute the rest of the in-vivo acylation of HlyA in two different clinical 
E. coli isolates (Lim et al., 2000). Both acylation sites in the HlyA genome function 
independently of one another with respect to the kinetics of their interaction with acyl-
HlyC (Langston et al., 2004). By using deleted protoxin variants and protoxin peptides as 
substrates in an in-vitro maturation reaction dependent on only HlyC and acyl-ACP, two 
independent HlyC-recognition domains were identified on the HlyA protoxin, each of 
which spanned one of the target lysine residues (Stanley et al., 1996). Each domain 
required 15 to 30 amino acids for basal recognition and 50 to 80 for full wild-type 
acylation, but HlyC recognized a large topology rather than a linear sequence. The loss of 
the Lys 564 acylation site either by mutation or structural deletion affected the 
thermodynamics of the acylation reaction at Lys 690, implying an undefined connectivity 
between the two acylation sites (Worsham et al., 2005). Nevertheless, the intact acylation 
at Lys 690 is essential for HlyA activity. 
www.intechopen.com
 
E. coli Alpha Hemolysin and Properties 
 
111 
No other HlyA sequences are required for toxin maturation, including the immediately C-
terminal Ca+2 binding repeats. Indeed, in vitro, Ca+2 ions prevent acylation at both sites 
(Stanley et al., 1996). The extreme sensitivity of the proHlyA activation reaction to free Ca+2 
supports the view that intracellular Ca+2 levels in E. coli are too low to affect toxin activity 
and that Ca+2 binding does not occur until the toxin is outside the cell. 
This posttranslational modification is remarkable because the behavior of the protein is 
changed by lipid modification from a benign protein to a frank toxin—part of this 
transformation being an exclusive mechanism in prokaryotes since in only a few eukaryotic 
proteins is this type of acylation found (for example, in the nicotinic acetylcholine receptor; 
the insulin receptor; and cytokines such as TNF-ǂ, IL-1ǂ and IL-1ǃ) (Stanley et al., 1998). In 
the following section we discuss the role that these covalently bound fatty acids play in the 
toxin's mechanism of action. 
2.3 The secretion of HlyA into the extracellular medium 
Maturation increases the hydrophobicity of the protein, but that property is not required for 
export (Ludwig et al. 1987). E. coli HlyA-related toxins are all secreted across both 
membranes by the type-I export process employing an uncleaved C-terminal recognition 
signal (Nicaud et al., 1986), (Stanley et al., 1991), but no N-terminal leader peptide (Felmlee et 
al., 1985) or periplasmic intermediate (Felmlee & Welch, 1988), (Koronakis et al., 1989). The 
HlyA secretory apparatus comprises HlyB (an inner-membrane traffic ATPase, the ATP-
binding cassette), HlyD (a membrane-fusion protein), and TolC (an outer-membrane 
protein) (Schulein et al.,1992), (Wandersman & Delepelaire, 1990), (Wang et al., 1991). In E. 
coli and most other pathogens, TolC is encoded by a separate gene from hlyCABD. As 
mentioned before (cf. Section 2.0) the type-I-secretion–signal sequences have been located 
within the last 60 C-terminal amino acids, consisting of 2 ǂ-helices separated by 8-10 
charged residues (Hui et al., 2000). 
The mechanism of exportation of HlyA is as follows: The trimeric accessory protein HlyD has 
been proposed to form a substrate-specific complex with the inner-membrane protein HlyB, 
which latter species subsequently recognizes the C-terminal signal peptide of HlyA. Upon the 
binding of HlyA, the HlyD trimer interacts with the trimeric TolC protein of the outer 
membrane, inducing a conformational change and the consequent export of HlyA. This 
assembly between the complex HlyB-HlyD with TolC very likely occurs because, as has been 
demonstrated by X-ray crystallography, the trimeric complex of TolC is very similar in size to 
the trimeric structure of HlyD, thus facilitating the formation of a continuous transperiplasmic 
export channel through which HlyA can pass (Koronakis et al., 2000). This complex appears to 
be transient, with it disengaging and reverting to a resting state once the substrate has been 
transported (Thanabalu et al., 1998). The energy necessary for the secretion process depends 
not only on ATP hydrolysis mediated by HlyB but also on the proton motive force exerted on 
the inner membrane (Koronakis et al., 1991, 1995). Type-I secretion is generally assumed to 
involve the translocation of unfolded proteins (Young & Holland, 1999), although Pimenta et al 
(2005) have suggested that contact with HlyD directly or indirectly affects the folding of HlyA 
either during the latter's transit through the translocator or afterwards. 
In the last decade many researchers have been interested in this type of secretion machinery 
because of its potential use in the export of chimeric proteins and in vaccine production 






Although HlyA has its own machinery for export from the bacteria, the presence of a 
physiologically active HlyA in the outer-membrane vesicles (OMVs) of clinical-hemolytic 
(Balsalobre et al., 2006) as well as laboratory-recombinant strains of E. coli (Herlax et al., 2010) 
has recently been demonstrated. 
OMVs are constantly being discharged from the surface of Gram-negative bacteria during 
bacterial growth. All Gram-negative bacteria studied to date, including E. coli, produce 
OMVs; and their release is increased when the bacteria are exposed to stressful conditions 
such as antibiotics or serum. Even though the release of OMVs could not be demonstrated in 
vivo, the presence of particles resembling those vesicles has, in fact, been detected in plasma 
from patients with different infectious processes (Beveridge, 1999). OMVs serve as secretory 
vehicles for the proteins and lipids of Gram-negative bacteria and in this manner play roles 
in establishing a colonization niche for carrying or transmitting virulence factors into host 
cells or otherwise modulating the host defense and response, thus acting as well as long-
range virulence factors that can protect luminal cargo from extracellular host proteases and 
so penetrate into tissues more readily than the larger bacteria (Kuehn & Kesty, 2005). In 
addition to toxin-protein delivery, other roles have been characterized for OMVs—namely, 
interspecies interaction and communication during multispecies infections plus DNA 
uptake and transfer (Mashburn-Warren & Whiteley, 2006). In the particular example of 
HlyA, we have demonstrated that the toxin secreted in this way is transferred to the target 
cell in a concentrated manner and as such is more hemolytically efficient than the free HlyA 
(Herlax et al., 2010). Moreover, Balsalobre et al. (2006) demonstrated that the HlyA 
associated with OMVs is protected from the attack of proteases, thus facilitating the survival 
of the toxin within the adverse medium of a patient’s plasma. 
2.4 The mechanism of action of HlyA 
HlyA belongs to one class of a wide range of host-cell-specific toxins. HlyA acts on a variety 
of cell types from several species—e. g., red blood cells, embryo and adult fibroblasts, 
granulocytes, lymphocytes, and macrophages (Cavalieri et al., 1984)—and also binds to and 
disrupts protein-free liposomes (Ostolaza et al., 1993). 
The host environments encountered by the ExPEC are extremely nutrient-poor; and the 
function of HlyA has generally been thought to be primarily the destruction of host cells, 
thereby facilitating the release of nutrients and other factors, such as iron, that are critical for 
bacterial growth. The lytic mechanism of HlyA is a complex process. Three stages seem to 
be involved that ultimately lead to cell lysis: binding, insertion, and oligomerization of the 
toxin within the membrane. 
Studies that have explored the binding of HlyA to membranes and the characterization of a 
putative toxin-specific receptor have produced contradictory results. First, the lymphocyte 
function-associated antigen (LFA-1) (CD11a/CD18; ǂ1ǃ2 integrin), was reported to serve as 
the receptor for HlyA on polymorphonuclear neutrophils (Lally et al., 1997) and HlyA was 
found to recognize and bind the N-linked oligosaccharides to their ǃ2-integrin receptors 
(Morova et al., 2008). This finding raises the possibility that the initial binding of the toxin to 
various cells might occur through the recognition of glycosylated membrane components, 
such as glycoproteins and gangliosides. Recently, Cortajarena et al. (2001) found that HlyA 
binds to the glycophorin of horse erythrocytes and that this binding was abolished by a 
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trypsinization of the membranes. In addition, these authors found that the glycophorin 
purified from erythrocyte ghosts and reconstituted in liposomes significantly increased 
liposomal sensitivity to HlyA. Amino acids 914-936 of HlyA were subsequently 
hypothesized to be responsible for binding to the ghost receptor (Cortajarena et al., 2003). 
Other studies, however, indicated that the binding of HlyA to cells occurred in a 
nonsaturable manner and that the toxin did not interact with a specific protein receptor 
either on granulocytes or erythrocytes (Valeva et al., 2005). Nevertheless, HlyA produces 
protein-free liposome disruption. Ostolaza et al. have reported that HlyA causes the release 
of fluorescent solutes following a so-called all-or-none mechanism. Using large unilamellar 
vesicles of different lipid compositions, the authors found that the vesicles composed of 
phosphatidylcholine, phosphatidylethanolamine, and cholesterol at a molar ratio of 2:1:1 
were the most sensitive (Ostolaza et al., 1993). These results demonstrated that the presence 
of a receptor was not necessary for hemolysis to occur. These contradictory findings 
regarding the presence or absence of a toxin-specific receptor might be related to the 
different amounts of toxin and/or the different types and animal species of target cells used 
in the various studies. At all events, the interaction of HlyA with a target-cell membrane 
devoid of any specific proteinaceous receptor appears to occur in two steps: an initial 
reversible adsorption of the toxin that is sensitive to electrostatic forces followed by an 
irreversible membrane insertion (Bakás et al., 1996), (Ostolaza et al., 1997). Studies with the 
isolated calcium-binding domain of HlyA revealed that that part of the protein may be 
adsorbed onto the membrane during the early stages of HlyA-membrane interaction 
(Sanchez-Magraner et al., 2007). 
The next step in the hemolytic process is the insertion of the toxin into the membrane. 
Hyland et al. (2001) demonstrated that the major region of HlyA that inserts into the 
membrane is located between residues 177 and 411. The insertion is furthermore 
independent of membrane lysis since HlyA-protein mutants that are completely nonlytic 
can insert into lipid monolayers (Sanchez-Magraner et al., 2006). In addition, a binding of 
calcium to the toxin was shown to induce a protein conformational change that made the 
insertion process irreversible (Sanchez-Magraner et al., 2006), (Bakás et al. 1998). Once the 
toxin is inserted, an oligomerization process occurs. We previously found that the fatty acids 
covalently bound to the toxin induce conformational changes that expose intrinsically 
disordered regions so as to promote protein-protein interactions. Thus, the oligomerization 
process of the toxin is facilitated by microdomains within the membrane (Herlax & Bakas, 
2007), (Herlax et al., 2009). 
The HlyA pore that is formed is highly dynamic because the size depends on both the 
interaction time and the concentration of the toxin (Welch, 2001). We recently demonstrated 
that the pore is of a proteolipidic nature since the conductance and membrane lifetime are 
dependent on membrane composition (Bakas et al., 2006). 
Nevertheless, what is not clear is how often HlyA reaches levels that are high enough to lyse 
host target cells during the course of an infection. In fact, sublytic concentrations of HlyA 
may even be more physiologically relevant. Indeed, recent studies have demonstrated that 
sublytic concentrations of a number of pore-forming toxins can modulate a variety of host 
signaling pathways, including the transient stimulation of calcium oscillations, the 






acetylation patterns (Hamon et al., 2007), (Ratner et al., 2006). In addition, sublytic 
concentrations of HlyA have been recently found to potently stimulate the inactivation of 
the serine/threonine protein kinase B (PKB), which enzyme plays a central role in host cell-
cycle progression, metabolism, vesicular trafficking, survival, and inflammatory-signaling 
pathways (Wiles et al., 2008). These findings may help to explain previously published 
results implicating sublytic concentrations of HlyA in the inhibition of chemotaxis and in 
bacterial killing by phagocytes in addition to the HlyA-mediated stimulation of host 
apoptotic and inflammatory pathways (Cavalieri & Snyder, 1982), (Koschinski et al., 2006), 
(Mansson et al., 2007), (Tran Van Nhieu et al.,2004), (Uhlen et al., 2000). 
3. Role of the fatty acids covalently bound to HlyA 
In general, lipid moieties play central roles in protein function—e. g., the targeting into 
membranes, an increase in the affinity for biological membranes, and an enhancement of 
protein-protein interactions (Stanley et al., 1998), (Chow et al., 1992). 
After a brief introduction to the general aspects of HlyA in the following section, we will 
describe the role that covalently bound fatty acids play in the mechanism of action of the 
toxin, from its initial activation to its final functioning in the target cell. This 
posttranslational modification must be critical since the presence of fatty acids transforms 
the innocuous proHlyA into the virulent toxin HlyA. 
3.1 Exposure of intrinsically disordered regions 
After the initial activation of HlyA by acylation, the toxin is exported into the extracellular 
medium by the type-I secretion system and by OMVs. None of the secretion routes are 
acylation-dependent, although the extracellular transport yield was found to be lower for 
proHlyA compared to that for HlyA. In addition, a high concentration of ProHlyA was 
found in inclusion bodies (Sanchez-Magraner et al., 2006). For comparative studies where 
acylated and nonacylated proteins were used, proHlyA was obtained from E. coli DH1—it 
having been transformed by a recombinant plasmid, pSF4000∆BamHI, in whose DNA a 
portion of the hlyC gene had been deleted. This strain secreted a full-length, but inactive 
hemolysin. Fatty acids were not necessary for the secretion of the toxin by OMVs, or by 
the bacteria's own export machinery; but they were essential for the toxin's hemolytic 
activity (Boehm et al., 1990). 
Several steps are involved in the lytic mechanism of the toxin: a binding of calcium previous 
to the toxin's interaction with membranes, the binding to and insertion into membranes, and 
the oligomerization of the toxin to form the final lytic pore. We will discuss below to what 
extent covalently bound fatty acids influence the different steps. 
In the extracellular medium, HlyA must associate with calcium in order to bind to 
membranes in the lytically active form (Ostolaza & Goñi 1995), (Bakás et al., 1998). This 
second activation step is acylation-dependent because the calcium-binding capacity is 
lower in the unacylated protein (Soloaga et al., 1996). Once HlyA is calcium-activated, the 
toxin appears to have a two-stage interaction with membranes: first, a reversible 
adsorption that is sensitive to electrostatic forces; and second, an irreversible insertion 
(Bakás et al., 1996). The inserted HlyA behaves as an integral protein because this form of 
the toxin cannot be extracted without the use of detergents (Soloaga et al., 1999). 
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Nevertheless, proHlyA, though nonacylated, also interacts with membranes. This 
observation is not surprising because the amino-acid sequence of the polypeptide shows 
amphipathic helices in the 250–400 amino-acid region. Despite the amphipathic stretches 
known to be essential for lytic activity, however, proHlyA is unable to alter the bilayer 
permeability (Soloaga et al., 1999). Experiments on protein adsorption at an air-water 
interface suggested that the fatty acids present in HlyA, unlike those in proHlyA, did not 
modify the surface-active properties of the protein and that the main difference between 
the precursor and the mature protein was that the proHlyA was virtually unable to insert 
itself into lipid monolayers (Sanchez-Magraner et al., 2006). Furthermore, we found that 
the presence of two acyl chains in HlyA confers on this protein the property of irreversible 
binding to membranes, which feature is essential for the lytic process to take place (Herlax 
& Bakas, 2003). In summary, although fatty acids covalently bound to HlyA help the toxin 
to bind calcium in order to adopt a competitive conformation for interaction with 
membranes, the absence of these fatty acids does not modify that interaction of the toxin, 
so that these fatty acids must play some other relevant role. The answer is that the fatty 
acids expose intrinsically disordered regions of the toxin that are involved in a different 
step within the mechanism of action. 
HlyA has a molten-globule conformation promoted by the presence of acyl chains, as 
demonstrated by a lower denaturing concentration of guanidinium-chloride. Other 
characteristics demonstrating this conformation were the binding of a higher number of 8-
anilinonaphtalene-1-sulfonate (ANS) molecules to HlyA with a weaker affinity, a higher 
efficiency of energy transfer from tryptophan to the bound ANS, and a faster digestion of 
HlyA with trypsin compared to the same reactions with proHlyA (Herlax & Bakas, 2007). 
The acylated protein was more stable in the absence of denaturant than the unacylated form, 
as demonstrated by the higher ∆G°H2O value for HlyA compared to proHlyA. Acyl chains 
covalently bound to the protein, however, promote a steric hindrance that contributes to a 
more relaxed structure, which acylated form can thus be denatured at a lower guanidinium-
chloride concentration. 
ANS binding to ordered regions can be distinguished from the binding to molten-globule-
like regions by differences in the apparent binding constant. The exceptionally high value of 
ANS bound to HlyA and proHlyA might result from amphipathic regions in both forms, but 
the presence of fatty acids has been observed to double this value because of the molten 
structure those lipids impart. The binding of a large number of ANS molecules in a weak 
manner is characteristic of the loose structure of the molten conformation. ANS binding to 
pockets in ordered or molten-globule proteins operationally gives apparent Kd values that 
differ by more than a factor of 5; thus, despite the uncertainties involved, these apparent Kd 
values serve as a diagnostic probe to distinguish ordered from molten proteins (Bailey et al., 
2001). This structural difference was also observed between the HlyA and proHlyA Kd 
values, demonstrating by an independent means that the fatty acids on the former induce a 
molten structure. Moreover, the higher fluorescence-transfer efficiency for HlyA compared 
to that for proHlyA indicated that the quenching of tryptophan fluorescence was more 
effective when the binding of ANS to the molten-globule conformation took place, where 
the accessibility of both the surface and inner tryptophan residues was increased. Thus, the 







Proteins with molten-globule-like regions are included in the category of intrinsically 
disordered proteins, as recently reviewed elsewhere (Dunker et al., 2001). Most of the 
disordered regions of proHlyA that were predicted through the use of the predictor of 
naturally disordered regions (PONDR) were located in the C-terminal half of the protein 
(Fig. 2). These domains could be related to the different steps in this toxin's mechanism of 
action from its export from the bacterium to pore formation in the target cell. 
HlyA carries a carboxy-terminal–secretion signal located within the last 50–60 amino acids 
(Jarchau et al., 1994). This region is predicted to be disordered; and although export of the 
toxin has been observed to be acylation-independent (Ludwig et al., 1987), as mentioned 
above, the yield from extracellular transport for proHlyA was lower than that for HlyA. 
Consequently, covalently bound acyl chains can expose these signal regions and thus 
facilitate transport. 
Intrinsically unstructured proteins can bind in several different patterns through a process 
termed binding promiscuity. The intrinsic lack of structure can confer functional advantages, 
including the ability to bind—perhaps in various conformations—to several different target 
cells. This binding promiscuity would furthermore explain the previously mentioned 
ambiguity in experimental determinations of the presence of a specific receptor for HlyA 
published to date (Lally et al., 1997), (Cortajarena et al., 2001), (Valeva et al., 2005). 
Many studies have searched for the presence of a receptor for HlyA in different target cells. 
For example, CD11a and CD18, the two subunits of ǃ2-integrin, were identified as cell-
surface receptors that mediate HlyA toxicity in the human target cells HL60 (Lally et al., 
1997). This receptor was found in most circulating leukocytes (lymphocytes, neutrophils, 
monocytes, and macrophages). Despite the absence of studies identifying the protein region 
responsible for the interaction with this receptor, studies on the adenylate-cyclase-
containing hemolysin of Bordetella pertusis (CyaA)—another RTX toxin—revealed that the 
main integrin-interacting domain of CyaA is located in its glycine/aspartate-rich repeat 
region; which stretch is characteristic of all protein members of this family. These results 
allowed the identification of region 1166–1287 as a major CD11b-binding motif (Azami-El-
Idrissi et al., 2003). Because this domain is involved in calcium binding, the authors 
proposed that CyaA shifts from a disordered structure to an R-helical conformation upon 
calcium binding to the RTX motifs (Rose et al., 1995); therefore, the speculation that the 
calcium-binding domain composed of glycine-rich tandem repeats corresponding to amino 
acids 550–850 of HlyA might be involved in the binding to ǃ2-integrin is tempting. That 
these regions also match the disordered regions predicted and that acyl chains might be 
implicated in the exposure since the calcium-binding capacity of proHlyA is lower than that 
of HlyA, should also be borne in mind (Soloaga et al., 1996). 
As cited above in Section 2.4, another protein identified as a receptor of HlyA in horse 
erythrocytes is the glycoprotein glycophorin (Cortajarena et al., 2001). A glycophorin-
binding region between residues 914 and 936 accordingly has been identified (Cortajarena 
et al., 2003). Previous sequence analyses of several RTX toxins had revealed that this 
stretch was a conserved region. If this region was deleted, the specific binding of HlyA to 
the cell-surface receptors on erythrocytes was lost without affecting its nonspecific 
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The role of fatty acids in the exposure of disordered regions is supported by results 
published for the D12-monoclonal-antibody–epitope reactivity. The D12 epitope maps to 
amino acids 673–726. Since the D12 monoclonal antibody reacts with HlyA, but not with 
proHlyA; the acylation of the former is directly responsible for the exposure of the epitope 





Fig. 2. ProHlyA is activated by acylation.  
This process is catalyzed by HlyC, which species transfers a fatty acid from ACP to two 
internal lysines of ProHlyA (Lys 564 and Lys 690). Once covalently bound, these fatty 
acids induce a molten-globule conformation in HlyA that exposes intrinsically disordered 
regions, the existence of which zones was predicted by the predictor of naturally 
disordered regions PONDR. The amino-acid sequence is represented on the x-axis, and 
the prediction of disorder on the y-axis. Peaks >0.5 are strongly predicted to be disordered 






3.2 Promotion of protein oligomerization 
Lipid binding to proteins can also be a determinant of specific protein-protein interactions 
such as the assembly of proteins into oligomeric complexes. This circumstance obtains for 
HlyA, where an oligomer was found at lytic concentrations in sheep-erythrocyte ghosts. In 
contrast, no oligomeric structure was found for proHlyA (Herlax et al., 2009). 
Fluorescence-Resonance-Energy Transfer (FRET) is a photochemical process whereby one 
fluorescent molecule or fluorophore, the "donor", upon excitation by an initial photon of 
light, spontaneously transfers its energy to another molecule, the "acceptor", by a 
nonradioactive dipole-dipole interaction (Forster, 1959). The distance over which energy can 
be transferred depends on the spectral characteristics of the fluorophores, but is generally 
within the 10–100-Å range. Hence, FRET can be used for measuring structure (Lakowicz et 
al., 1990), conformational changes (Heyduk, 2002), and interactions between molecules 
(Parsons et al., 2004). Since HlyA does not contain cysteine residues in its sequences, lysine 
344 was replaced by a cysteine (HlyA K344C) and the same point mutation introduced into 
the unacylated protein (proHlyA K344C). The aim of this point mutagenesis was to permit 
the binding of only one fluorescent probe per protein, where that mutation—hopefully 
located in the insertion region of the toxin into membranes (Hyland et al., 2001)—would not 
affect the hemolytic activity of the toxin. To carry out this study, two populations of HlyA 
K344C mutant proteins, one labelled with donor (Alexa-488) and the other with acceptor 
fluorophores (Alexa-546), were bound to sheep-erythrocyte ghosts. Our report showed that 
an oligomer was involved in the hemolytic mechanism of HlyA (Herlax et al., 2009). FRET 
can be used to study the distribution of molecules in membranes because the average 
spacing between molecules of interest will depend primarily on their lateral arrangement. 
Molecules may be within FRET distance either because they are clustered or because they 
are randomly distributed at such high surface densities that a fraction of them is within 
FRET proximity. The latter possibility was avoided in our experiments by using a high 
lipid/protein molar ratio (109) to insure that the observed FRET corresponded to 
oligomerization of the toxin on the erythrocyte surface. In comparison, the absence of FRET 
in the mutant protein, proHlyA K344C confirmed the participation of the covalently bound 
fatty acids in the oligomerization process. Fig. 3 shows the fluorescence spectra obtained in 
the FRET experiments for both proteins. Prima facie, this absence of FRET could be attributed 
to a reduced binding of the mutant protein to the erythrocyte ghosts, but this possibility was 
discarded because the percentage of binding to the membranes of both proteins was similar. 
We need to underscore here that fatty acids are essential for hemolytic activity; and 
considering that they are needed for oligomerization, we can state that oligomerization is 
necessary for hemolysis. We thus feel tempted to propose that the presence of fatty acids 
covalently bound to the protein leads to the exposure of regions that are implicated in 
protein-protein interactions. 
In addition, a critical role of acylation in the oligomerization process to form hemolytic 
pores has been proposed for the adenylate-cyclase toxin from Bordetella pertussis (cf. Section 
3.1) (Hackett et al., 1995). 
Finally, if we consider that pores formed by HlyA are sensitive to proteases on the cis side of 
the planar lipid membranes (Menestrina et al., 1987), we could propose the possibility that 
the part of the toxin remaining external to the membrane is involved in the protein-protein 
interaction responsible for oligomerization and thus participates in pore formation. 
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Fig. 3. Oligomerization of HlyA in erythrocyte ghosts. FRET calculated for HlyA K344C and 
proHlyA K344C bound to erythrocyte ghosts. The lipid/protein ratio was 109. Left inset: 
Example of spectra measured for HlyA K344C. Fluorescence-emission spectrum of 
erythrocyte ghosts containing donor/acceptor, FD/A(480,λem) (excited at 480 nm; blue triangle), 
emission spectrum of erythrocyte ghosts labelled only with donor, FD(480, λem) (violet circle), 
emission spectrum of erythrocyte ghosts containing D/A, FD/A(530, λem) (excited at 530 nm 
where only the acceptor absorbs; light blue square), and emission spectrum of erythrocyte 
ghosts labelled only with acceptor, FA(480, λem) (purple square). Right inset: The same emission 
spectrum as in the left inset but measured for ProHlyA K344C. 
3.3 Contrary to expectations, fatty acids do not facilitate the interaction of HlyA with 
membrane microdomains 
A variety of pathogens and toxins have been recognized as interacting with microdomains 
in the plasma membrane. These microdomains are enriched in cholesterol and sphingolipids 
and probably exist in a liquid-ordered phase, in which lipid acyl chains are extended and 
ordered (Brown & London, 1998). Many proteins are targeted to these membrane 
microdomains by their favorable association with ordered lipids. Interestingly, such 
proteins are linked to saturated acyl chains, which species partition well into those domains 
(Pike, 2003). Although covalently bound fatty acids had not been implicated in the targeting 
of HlyA to membranes, their involvement in the targeting to membrane microdomains was 
studied (Herlax et al., 2009). For this purpose—and taking into account that these 
microdomains are enriched in cholesterol and sphingolipids—the hemolytic activity of the 






erythrocytes. The hemolysis rate of the cholesterol-poor erythrocytes was lower than that 
of the control erythrocytes at each HlyA concentration tested, thus pointing to the 
participation of cholesterol-enriched microdomains in the oligomerization process. For 
cholesterol-depleted erythrocytes, at low toxin concentrations, the kinetics of hemolysis 
seemed to be more complex, suggesting that toxin diffusion in membranes is the rate-
limiting step. In order to determine if the decrease in the hemolytic rate observed in the 
cholesterol-depleted erythrocytes was caused by an impairment of toxin oligomerization, 
we repeated the FRET experiments comparing control and cholesterol-depleted sheep-
erythrocyte ghosts. We demonstrated that cholesterol depletion led to a decrease in FRET 
of 75% compared to the control sheep ghosts. This result indicated that cholesterol-
enriched microdomains played a significant role in the oligomerization process. To obtain 
more information about the effect of cholesterol-enriched microdomains within the 
oligomerization process, we performed FRET-kinetics experiments. The role of cholesterol 
was confirmed by the results of FRET kinetics, where the biphasic behavior of FRET 
suggested the initial formation of small oligomers, followed by their assembly to form 
multimeric structures (Fig. 4). The concentration of the small oligomers was favored by 
the cholesterol-enriched microdomains, where the diffusion time in the membrane 
became diminished. The number of HlyA molecules that became associated to form the  
 
 
Fig. 4. FRET kinetics. Measurement of acceptor fluorescence at 570 nm as a function of time in a 
mixture composed of HlyA K344C labelled with fluorescent donor and acceptor plus either 
control erythrocytes (black line) or cholesterol-depleted erythrocytes (light gray line). 
Measurement of a mixture of unlabelled and labelled with acceptor HlyA K344C with control 
erythrocytes (dark gray line) was done as FRET-negative control. Assays were performed at a 
ratio of 5 µg of total toxin per 100 µg of phospholipids (as erythrocyte membranes). The 
excitation and emission monochromators were set at 480 nm and 570 nm, respectively. Alexa-
546 emission was measured at a rate of 25 samples/s for 240 s, at 37°C. The curves represent 
the average value of three independent experiments containing five replicates each. 
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pore was uncertain; nevertheless, the assumption that several molecules could 
oligomerize to form a pore was not unreasonable. An extension of this reasoning 
suggested that at high doses a progressive oligomerization of HlyA leads to the fusion of 
the pore and rapid destruction of the cell membrane with little time for activation of the 
central apoptotic pathway. By contrast, at lower concentrations, the pores would be 
smaller and fewer in number so that the cells, though injured, would survive long enough 
for apoptosis to be observed (Lally et al., 1997). These results can explain why toxin 
association with erythrocytes at 0–2°C is characterized as a prelytic state, whereas 
following a shift to 23°C—and after a lag period—lysis begins (Moayeri & Welch, 1997). In 
conclusion, the fusion of oligomers may be the rate-limiting step in pore formation, and 
the integrity of the cholesterol-enriched microdomains is necessary for the concentration 
of HlyA to induce hemolysis. This notion agrees with the findings of Moayeri and Welch 
(Moayeri & Welch, 1994), who observed that the degree of osmotic protection of 
erythrocytes afforded by protectants of varying sizes depended on the amount of toxin 
applied and the duration of the assay. These authors suggested that HlyA creates a lesion 
with a very small initial size that then increases in apparent diameter over time. 
Consequently, the larger the oligomer is, the bigger the pore size becomes. 
That the terms "membrane microdomains" and "detergent-resistant microdomains" 
(DRMs) are not synonymous is essential to remember because the two have different 
origins and conceptual meanings (Lichtenberg et al., 2005). The DRM technique, though, is 
widely used in the current literature to investigate the interaction between a protein and 
membrane microdomains. This technique takes advantage of the selective solubilization 
of different lipids that occurs when a biomembrane is submitted to the action of a 
nonionic detergent such as Triton X-100. When erythrocyte ghosts were incubated with 
HlyA and the DRMs were separated by sucrose-gradient ultracentrifugation, the 
immunoblot analysis revealed that most of the ghost-associated HlyA was localized in the 
DRMs, indicating that the binding of HlyA to the erythrocyte membranes was mediated 
by membrane microdomains that served as concentration platforms for the toxin's 
oligomerization. That proHlyA colocalizes with HlyA and flotillin (a microdomain 
protein marker) in DRMs emphasizes our hypothesis that the main role of the saturated 
acyl chain covalently bound to HlyA is a participation in the oligomerization process, and 
not the targeting to cholesterol-enriched membranes (Fig 5). 
A key feature of cholesterol-enriched microdomains is the tight packing of lipid acyl chains 
in the liquid-ordered phase, where the lipid acyl chains are extended and ordered (Brown & 
London, 1998). Because of the difficulty in packing membrane-spanning helices into the 
ordered lipid environment, some proteins are linked to saturated acyl chains and partition 
well into those microdomains (de Planque & Killian, 2003). Shogomori et al. (2005) found, 
however, that acylation did not measurably enhance microdomain association, and they 
concluded that the acylated linker for the activation of T-cell transmembrane domains had a 
low inherent affinity for cholesterol-enriched microdomains. The possible inferrence is that 
acylation is not sufficient for the targeting of any transmembrane protein and that therefore 
a second mechanism—such as protein-protein interactions for microdomain associations—is 
required (Fragoso et al., 2003), (Cherukuri et al., 2004). 
To conclude, we propose that fatty acids covalently bound to HlyA and membrane 






induce the exposure of intrinsic disordered regions in the toxin so as to enhance protein-
protein interactions in order to form the oligomer, while the membrane microdomains act as 
platforms for the concentration of the toxin during the oligomerization process. 
 
 
Fig. 5. Interaction of HlyA with DRMs.Thirty µg of HlyA were incubated with 100 µl of 
erythrocyte ghosts for 30 min at 37 °C. Cells were lysed with 1% (v/v) Triton X-100 and 
insoluble cell components separated by sucrose-density-gradient centrifugation. The 
gradient fractions were analyzed by immunoblotting with anti-HlyA antibodies. HlyA was 
present in fractions 3 and 4. Gradient fractions were also analyzed by immunoblotting with 
anti-Flotillin-1 antibodies. Flotillin-1 appears mainly in fractions 3 and 4. ProHlyA was 
incubated under the same conditions as HlyA. The gradient fractions were analyzed by 
immunoblotting with anti-HlyA antibodies. ProHlyA colocalizes with HlyA. 
In summary, fatty acids covalently bound to HlyA induce a molten-globule structure in the 
toxin, exposing intrinsically disordered regions involved in the different steps in the toxin's 
mechanism of action. Fatty acids expose specific regions that induce protein-protein 
interaction in the oligomerization process that takes place within the membrane 
microdomains of erythrocytes. The irreversibility of the toxin's membrane binding 
promoted by fatty acids might result from the formation of the HlyA oligomeric structure 
(Herlax & Bakas, 2003,2007), (Herlax et al., 2009). 
4. Toxin-based theraphy 
Bacterial toxins have been defined as "soluble substances that alter the normal metabolism 
of host cells with deleterious effects on the host" (Schlessinger & Schaechter, 1993). 
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investigators have sought ways of obtaining benefits from toxins. In the present section we 
will discuss these toxin-based therapies and the possible relevant use of HlyA. 
4.1 Immunotoxins 
Conventional cancer treatments such as surgery, chemotherapy, and radiotherapy often fail 
to achieve complete cancer remission. Moreover, radiotherapy and/or chemotherapy are 
almost always cause significant—and sometimes long-lasting—side effects. These 
considerations have prompted the development of many new approaches for the treatment 
of cancer. One such example involves the use of immunotoxins (Bernardes et al., 2010). 
The term "immunotoxin" classically refers to chimeric proteins with a cell-selective ligand 
chemically linked or genetically fused to a toxin moiety that can target cancer cells 
overexpressing tumor-associated antigens, membrane receptors, or carbohydrate antigens. 
In the 1970s the first therapeutic agents composed of toxins conjugated to antibodies against 
cell-surface antigens started to emerge as tumor-cell killers (Moolten & Cooperband, 1970), 
(Moolten et al., 1976). Since then, many hybrid molecules consisting of a toxin coupled to a 
specific targeting antibody or ligand were developed, with most of these hybrids being 
directed against tumor cells (Pastan et al., 2007). 
First-generation immunotoxins were prepared by chemically conjugating antibodies to 
natural intact toxin units or to toxins with attenuated cell-binding capability. These 
constructs, however, were heterogeneous and nonspecific both because multiplicities of 
potential sites were available for chemical conjugation and since the presence of the cell-
binding domain on the toxin led to an intoxication of nontumor cells as well. Immunotoxins 
of the second generation were also based on chemical conjugation between the targeting 
moiety and the toxin. Nevertheless, accumulated knowledge on the structure and function 
of the toxins enabled the removal of their native nonspecific cell-binding domain, thus 
generating immunotoxins that were much more target-specific when conjugated to 
monoclonal antibodies. Although more specific and thus better tolerated by animals, 
immunotoxins from this second generation were still chemically heterogeneous, and their 
large size hindered them from penetrating solid tumors. In order to avoid this 
heterogeneity, improve tumor penetration, and reduce production complexity and expense, 
recombinant-DNA techniques were applied in the production of the third-generation 
immunotoxins. In these constructs—mostly produced in the bacterium E. coli—the cell-
binding domain of the toxin is genetically replaced with a ligand or with the Fv portion of 
an antibody in which the immunoglobilin light- and heavy-chain variable regions are either 
genetically linked or held together by a disulfide bond (Shapira & Benhar, 2010). 
Among the bacterial toxins that were used for the construction of immunotoxins, the 
most common were the diphtheria toxin and the pseudomonas exotoxin A, which toxins 
are naturally produced by the Gram-positive, aerobic Corynebacterium diphtheria and by 
the Gram-negative, aerobic Pseudomonas aeruginosa, respectively. Clinical trials with 
different exotoxin A-immunotoxins have already been performed with positive results in 
leukemia and bladder cancer (Kreitman et al., 2001), (Kreitman et al., 2005), (Biggers & 
Scheinfeld, 2008). 
In spite of the promise shown by bacterial toxin-based chimeric proteins, these hybrids still 






proteins elicits a high degree of humoral response in humans. In addition, in developed 
countries, where people have become immunized against diphtheria, the patient's serum 
will have circulating antibodies against the diphtheria toxin that will result in a 
neutralization of diphtheria toxin-based immunotoxins (Hall et al., 2001). Both the 
Pseudomonas exotoxin and the diphtheria toxin are large molecules and are difficult to 
humanize. At sufficiently high concentrations these fusion proteins lead to symptoms like 
the vascular-leak syndrome and thus exhibit a certain degree of nonspecific toxicity. 
HlyA as a possible candidate toxin for the synthesis of immunotoxins  
Considering all the details of the structure and mode of action of HlyA discussed above, 
we can state that HlyA can be a good candidate for an effective immunotoxin. Although, 
certain additional details about the domains implicated in the binding of the toxin to 
target-cell receptors need to be clarified, we can consider that the domain that comprises 
amino acids 914–936 should be exchanged for the specific antibody (or ligand) chosen for 
interaction with the tumor cell of interest. Perhaps some amino acids within the repeat 
domain that might be involved in the interaction with the ß2-integrins should also be 
removed in the fusion protein. 
The reason for using HlyA in an immunotoxin 
An observation deserving emphasis is that the more relevant effects that HlyA produces 
during an infection are sublytic rather than cytolytic. Among these effects we must bear in 
mind the one related to the modulation of the host-signaling cascades, where HlyA was 
found to produce an inactivation of the PKB (cf. Section 2.4)—a key protein involved in 
several pathways related to host-cell survival, inflammatory responses, proliferation, and 
metabolism (Manning & Cantley, 2007), (Fayard et al., 2005). By inactivating PKB, HlyA is 
able to fine-tune host responses related to the inflammatory- and apoptosis-signaling 
cascades that are initiated during the course of an infection. PKB inactivation is produced 
by an extracellular calcium-dependent, potassium-independent process requiring HlyA 
insertion into the host plasma membrane and subsequent pore formation. Calcium influx 
induces the activation of host-protein phosphatases that dephosphorylate PKB, 
inactivating it and finally inducing host-cell apoptosis. Thus, if a ligand directed at a 
specific tumor-cell receptor is fused with HlyA, that immunotoxin might induce the 
apoptosis of the desired cell. 
The advantage of using HlyA is that the translocation of the immunotoxin into a tumor cell 
is not necessary, only its binding to the membrane where HlyA can insert itself and form the 
pore needed to execute its apoptotic action. Of course, these hypotheses are only 
possibilities that would warrant further investigation. 
4.2 Vaccines 
In recent years, an increase in the development of vaccination technology has taken place, 
but the ideal vaccine has not yet been found. In general terms, there are certain criteria that a 
vaccine must satisfy: it must be capable of eliciting the appropriate immune response; and it 
should be safe, stable, and reproducible (Perrie et al., 2008). 
UTIs caused by UPEC still represent an enormous challenge for the development of vaccines 
targeted to induce an immunity that can either prevent the infectious agent from attaching 
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to and colonizing the mucosal epithelium and/or can block the binding and action of 
microbial toxins, such as HlyA (Holmgren et al., 2003). Since the infections by these bacteria 
occur at, or take their departure from, a mucosal surface; a mucosal route of vaccination 
should be selected rather than a parenteral one. 
A significant aspect of immune responses at mucosal surfaces is the production of a 
secretory IgA (S-IgA) and its transport across the epithelium. This S-IgA response 
represents the first line of defence against the invasion by bacterial pathogens. The 
mucosal immune system is an integrated network of tissues, cells, and effector molecules 
that functions to protect the host from those pathogens. Furthermore, mucosal 
lymphocytes exhibit unique homing receptors, the integrins, that recognize ligands 
expressed on mucosal endothelial cells so as to allow their retention within mucosal 
tissues for the delivery of cellular and humoral immune responses (Butcher & Picker, 
1996). Because of the presence of specific interconnected mucosal induction and effector 
sites for eliciting the S-IgA antibody response, the mucosal immune system has been 
shown to be separated from the peripheral immune system. Thus, the induction of 
peripheral immune responses by parenteral immunization does not necessarily result in 
significant mucosal immunity; by contrast, mucosal immunization is capable of inducing 
immune protection in both the external secretions and the peripheral immune 
compartments (Kiyono et al., 1992), (McGhee et al., 1992). 
The induction of immune responses following mucosal immunization is usually dependent 
upon the coadministration of the appropriate adjuvants that can initiate and support the 
transition from innate to adaptive immunity. While a number of substances of bacterial 
origin have been tested as mucosal adjuvants, the most widely used mucosal adjuvants in 
experimental animals are the cholera toxin (CT) and the closely related E. coli heat-labile 
enterotoxin (LT). Both CT and LT consist in homopentamers of cell-binding B subunits 
associated with a single toxically active A subunit. The A subunit enzymatically ADP-
ribosylates the Gs protein of adenylate cyclase leading to an increased cAMP production in 
the affected cells (de Haan & Hirst, 2000). CT and LT can alter several steps in the induction 
of a mucosal immune response. These effects, which alone or in combination might explain 
their strong adjuvant action after oral immunization, include: (1) an increased permeability 
of the intestinal epithelium leading to an enhanced uptake of a coadministered antigen, (2) 
an enhanced antigen presentation by various antigen-presenting cells, (3) a promotion of 
isotype differentiation in B cells leading to increased IgA formation, and (4) complex 
stimulatory as well as inhibitory effects on T-cell proliferation and cytokine production. 
Finally, CT and LT have been shown not only to avoid an induction of oral tolerance but 
also to abrogate additional otherwise efficient regimens producing tolerance induction after 
oral antigen administration (Holmgren et al., 2005). 
A number of studies have examined the activity of LT and CT as mucosal adjuvants in 
vaccines against a variety of bacterial, fungal, and viral pathogens. Representative examples 
include the tetanus toxoid (Xu-Amano et al., 1993),  (Yamamoto et al., 1996), (Cheng et al., 
1999), (Xu-Amano et al., 1994), the inactivated influenza virus (Hashigucci et al., 1996), 
(Tumpey et al., 2001), a recombinant urease from Helicobacter spp. (Lee et al., 1995), (Weltzin 
et al., 1997), (Lee, 2001), and the pneumococcal surface protein A from S. pneumoniae (Wu et 
al.,1997). Many other examples have been reported, and all these studies clearly indicate that 






antigens. Nevertheless, both LT and CT are potent enterotoxins, and this property has 
seriously limited the practical use of these molecules (Freytag & Clements 2005). To avoid 
such toxicity, a number of nontoxic mutant derivatives of CT or LT have been proposed 
(Douce G, 1997) (Douce et al. 1998). In particular, single-amino-acid-substitution mutants of 
LT (R7K, S63K and R192G) that lack ADP-ribosyltransferase activity have been shown to 
retain their adjuvant properties (Douce et al. 1995). 
In contrast, because of their size, plasticity, and safety profile in humans, OMVs are attractive 
vehicles for vaccine delivery. OMV vaccines for serogroup-B meningococcal disease, 
consisting in vesicles from Salmonella thyphimurium and Pseudomonas aeruginosa that contain 
surface antigens native to the pathogens have been shown to exhibit immunogenic properties 
(Alaniz et al., 2007), (Bauman & Kuehn, 2006). Two vaccines for serogroup-B meningococcal 
disease currently exist that are formulations comprising bacterial surface antigens that have 
been naturally incorporated into OMVs (Oster et al., 2005), (Feiring et al. , 2006). These OMV-
based vaccines represent a novel system where both the antigen and delivery vehicle are 
derived from the Neisseria meningitidis pathogen itself (Claassen et al., 1996), (Arigita et al., 
2004). Moreover, genetically engineered OMVs offer an attractive possibility for use as easily 
purified vaccine-delivery systems capable of greatly enhancing the immunogenicity of low-
immunogenicity protein antigens without the need for an added adjuvant. 
With the development of controlled-release technologies, the engineering of OMVs emerged 
as a promising strategy for antigen delivery because these vesicles are similar in geometry to 
naturally occurring pathogens and are readily internalized by antigen-presenting cells, thus 
avoiding the complex manufacturing steps required to purify and encapsulate antigens into 
particulate delivery systems such as polymer particles (Singh et al., 2007), immune-
stimulating complexes (Morein et al., 1984), liposomes, proteosomes, and related vesicles 
(Lowell et al., 1988), (Lowell et al., 1988), (Felnerova et al., 2004), (Copland et al., 2005)—all of 
which processes render these approaches economically unfeasible (Ulmer et al., 2006). 
The genetic fusion of the green-fluorescent protein (GFP) as a model subunit antigen with the 
bacterial hemolysin ClyA resulted in a chimeric protein that elicited strong anti-GFP antibody 
titers in immunized mice, whereas immunization with GFP alone elicited no such titers. 
Similar to native unfused ClyA, the chimeric ClyA-fusion proteins were found localized in 
bacterial OMVs, where they retained the activity of the fusion partners, thus demonstrating for 
the first time that ClyA can be used to colocalize fully functional heterologous proteins directly 
in bacterial OMVs. The anti-GFP humoral response in mice immunized with the engineered 
OMV formulations was indistinguishable from the response to the purified ClyA-GFP fusion 
protein alone and was equal to the response to purified proteins adsorbed to aluminum 
hydroxide, a standard adjuvant. Engineered OMVs containing ClyA-GFP were easily isolated 
by ultracentrifugation, thus effectively eliminating the need for a laborious antigen 
purification from cell-culture expression systems (Chena et al., 2010). The retention of 
hemolytic-protein activity indicated that ClyA-antigen fusions maintained their 
conformations. Although no pathologic effects were observed in mice immunized with ClyA, 
a detoxification of the toxin through mutation, truncation, or chemical methods may attenuate 
any possible toxicity while still retaining the hybrid's immunomodulatory capabilities. 
On the basis of all these data, HlyA presents many properties that can be considered when 
designing a vaccine. 
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Anti- UPEC vaccine: The urinary tract is one of the most common sites of bacterial 
infection. As mentioned above, over half (53%) of all women along with 14% of men 
experience at least one UTI in their lifetime (Griebling, 2005), (Griebling, 2005). E. coli is 
the infectious agent in more than 80% of the uncomplicated UTIs (Marrs et al., 2005), 
(Foxman & Brown, 2003). In addition, the upper UTIs of young children can cause 
permanent kidney damage. An estimated 57% of children with acute pyelonephritis 
develop renal scarring (Lin et al., 2003). 
In recent years, an increase in the antibiotic resistance of UPEC isolates has been observed 
(Bours et al., 2010) that imposed an urgent need for alternative treatment and prevention 
strategies to combat this serious and widespread human pathogen. With this aim, much 
research has been focussed on the development of vaccines to stimulate protective 
immunity against UPEC. In those studies, surface-exposed molecules such as P fimbriae, the 
lipopolysaccharide core, ǂ-hemolysin, and the salmochelin receptor IroN have been utilized 
as antigens for subunit vaccines (Goluszko et al., 2005), (Russo et al.,2003), (O’Hanley et al., 
1991); but the limited success of these strategies prevented any vaccine from being currently 
available. One consideration is that this vaccine has to generate immune responses at the 
level of mucosal surfaces. 
Large-scale reverse-vaccinology approaches offer an alternative to the traditional vaccine 
design through applying genomic and bioinformatic methods to identify novel vaccine 
targets (Pizza et al., 2000). Using this technique, Alteri et al identified a class of molecules 
involved in iron acquisition as vaccine candidates and reported that intranasal 
immunization with this UPEC outer-membrane iron receptor generated an antigen-
specific humoral response to provide protection from UTI (Alteri et al., 2009). The authors 
proposed that the targeting of an entire class of molecules instead a single protein would 
permit the identification of components of a more generally protective UTI vaccine and 
that this strategy could be used in the development of vaccines to prevent infections 
caused by other pathogenic bacteria. During this present year, these same authors, using 
the in-vivo-induced–antigen technology, identified a novel UPEC virulence factor (tosA, a 
gene encoding a predicted repeat-in-toxin family member) that could be useful as a 
potential vaccine target (Vigil et al., 2011). Although this methodology did not identify 
HlyA as a potential candidate for this vaccine, the introduction of that toxin would be 
beneficial. First of all, HlyA has been recognized as one of the main virulence factors 
associated with the pathogenicity caused by UPEC (Wiles, Kulesus and Mulvey 2008); 
second, the toxin induced an immunity response in host organisms (O’Hanley et al., 1991) 
and thus is immunogenic in its native state; third, it can also produce focal leaks in 
intestinal epithelia (Troeger et al., 2007). Focal leaks are small openings within the 
epithelium where bacterial penetration occurs. HlyA induces such focal leaks in a 
proinflammatory environment—those being also induced by the secretion of the cytokines 
TNFǂ and IL-13. Of relevance to highlight is that HlyA can increase the permeability of 
the intestinal epithelium so as to lead to an enhanced uptake of a coadministered antigen, 
thus acting as both a coadjuvant and an antigen in its own right. The dose that induces 
this effect would naturally have to be extensively investigated. 
HlyA can also be used as adjuvants in any other vaccine design against another pathogen. 
For example, the toxin can be included in any liposomal vaccine in order to facilitate uptake 






OMV vaccines: Balsalobre et al (2006) demonstrated that physiologically active HlyA is 
associated with the OMVs produced from E. coli laboratory strains and also from natural 
and clinical isolates. In our laboratory, we found that the unacylated toxin (proHlyA) can 
also be associated with OMVs (Herlax et al., 2010). On the basis of this finding, OMV 
vaccines can be designed by effecting a fusion of the desired antigen with ProHlyA. In this 
way, ProHlyA would direct the exposure of the antigen on the surface of the OMVs without 
inducing any cytotoxic response. An advantage of OMV vaccines is that, because of their 
size and lipopolysaccharide content, they are able to induce an adequate immune response. 
Finally, mention must be made that these hypotheses are just speculative on the basis of 
what is known about the structure and function of HlyA, whose application in toxin-based 
therapy still has to be exhaustively investigated and especially the immune response the 
toxin might evoke. 
5. Conclusion  
E. coli is one of the predominant species of facultative anaerobes in the human gut and in the 
majority of the cases is harmless to the host. These strains are mostly commensals but also 
contain a group called the extraintestinal pathogenic E. coli (ExPEC). Usually the ExPEC are 
also harmless colonizers but under certain circumstances can translocate and cause infection. 
The main virulence factor responsible for this translocation is the HlyA toxin, which pathogen 
is mainly associated with severe UTI but in addition with bacteremia and extraintestinal 
infections. In this chapter an exhaustive description of the toxin has been delineated; including 
its synthesis, maturation, and export from the bacteria. Effects produced by HlyA in different 
target organs have also been discussed. The significance of the maturation process for the toxin 
cannot be understated. The acylation of the protein at two internal lysines gives the toxin its 
virulence, by exposing intrinsic disordered regions that are essential to different steps of the 
toxin's mechanism of action. The further exposure of regions involved in the protein-protein 
interaction within the oligomerization process is responsible for the permeability induced in 
all the target cells, despite the intracellular signal pathway the toxin induces in each specific 
organ. This activation is unique to prokaryotic proteins. 
Based on the already known structural and functional characteristics of HlyA, we might 
speculate about its use in toxin-based therapy. Such therapy is a versatile and dynamic 
research area with a great potential application. Further investigation, however, is required 
in order to improve the efficiency and safety of toxin-based agents. Investments in the 
development of delivery and targeting techniques are definitely needed in order to achieve 
this goal, though the basic research on the structure and mechanism of natural toxins should 
nevertheless not be abandoned. Topics related to HlyA have still to be clarified concerning 
the existence of a toxin-specific receptor in target cells and the domains of the toxin involved 
in its interaction with those putative binding sites. The deeper our knowledge becomes 
about this unique family of secreted polypeptides, the more easily will we be able to harness 
their great potential for our own benefit. 
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